Charles River Laboratories (CRL) Tops Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $230.57 -0.05%
Revenue Growth %: -5.1%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: -5.1%
Financial Fact:
Discontinued operations (in dollars per share): 0.01
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.75, $0.03 better than the analyst estimate of $2.72. Revenue for the quarter came in at $913.9 million versus the consensus estimate of $910.1 million.
GUIDANCE:
Charles River Laboratories sees FY2022 EPS of $11.50-$11.75, versus the consensus of $11.64.
- Revenue growth, reported 13.5% – 15.5%
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Morgan Stanley Resumes Kohl's (KSS) at Underweight
- Vertex to acquire Crinetics Pharmaceuticals for $10 billion
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
